Any legislative, regulatory or administrative action to correct the problem of increasing prices should be based upon a thorough understanding of the forces at play in the market and the interests of each class of trade in the drug manufacturing and distribution system. This book describes the complexities of the market for branded and generic drugs. An attempt to reduce FDA requirements to increase the number of generic competitors may endanger public health without resulting in a decrease in prices to end consumers. This book outlines some of the critical issues facing the healthcare industry today, in addition to providing a detailed blueprint for all aspects of running a successful pharmaceutical company. Executives and professionals in the pharmaceutical industry and other manufacturing based companies will benefit from Dr. Levitt's insights acquired over 50 years that enabled him to transform a small, unprofitable pharmaceutical company into a multi-billion-dollar global entity.